Zhengjun Lin

1.2k total citations · 2 hit papers
35 papers, 759 citations indexed

About

Zhengjun Lin is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhengjun Lin has authored 35 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhengjun Lin's work include Cancer-related molecular mechanisms research (12 papers), MicroRNA in disease regulation (7 papers) and Circular RNAs in diseases (7 papers). Zhengjun Lin is often cited by papers focused on Cancer-related molecular mechanisms research (12 papers), MicroRNA in disease regulation (7 papers) and Circular RNAs in diseases (7 papers). Zhengjun Lin collaborates with scholars based in China and United States. Zhengjun Lin's co-authors include Tang Liu, Zhihong Li, Yanlin Wu, Guoqing Li, Fu‐Xing‐Zi Li, Changchun Li, Su‐Kang Shan, Bei Guo, Ling‐Qing Yuan and Xiao Lin and has published in prestigious journals such as Cancer Research, Chemical Engineering Journal and The FASEB Journal.

In The Last Decade

Zhengjun Lin

31 papers receiving 752 citations

Hit Papers

Epigenetic regulation in metabolic diseases: mechanisms a... 2022 2026 2023 2024 2023 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
    2023 222 citations Yanlin Wu, Zhengjun Lin et al. Signal Transduction and Targeted Therapy profile →
  2. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential
    2022 197 citations Zhengjun Lin, Yanlin Wu et al. Molecular Cancer profile →

Peers

Zhengjun Lin
Zhongqiu Zhou China
Meng Ye China
Qingdong Guo China
Xiaoming Hou China
Dongmei Zhou China
Pinglin Lai China
Meng Xue China
Zhongqiu Zhou China
Zhengjun Lin
Citations per year, relative to Zhengjun Lin Zhengjun Lin (= 1×) peers Zhongqiu Zhou

Countries citing papers authored by Zhengjun Lin

Since Specialization
Citations

This map shows the geographic impact of Zhengjun Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhengjun Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhengjun Lin more than expected).

Fields of papers citing papers by Zhengjun Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhengjun Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhengjun Lin. The network helps show where Zhengjun Lin may publish in the future.

Co-authorship network of co-authors of Zhengjun Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Zhengjun Lin. A scholar is included among the top collaborators of Zhengjun Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhengjun Lin. Zhengjun Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Zhengjun, et al.. (2025). Lactylation‑mediated ferroptosis: A novel mechanism and therapeutic prospects in human diseases (Review). International Journal of Molecular Medicine. 57(2). 1–14.
2.
Lin, Zhengjun, et al.. (2025). Leveraging Artificial Intelligence for Neoantigen Prediction. Cancer Research. 85(13). 2376–2387. 5 indexed citations
3.
Zeng, Jing, Xianghong Zhang, Zhengjun Lin, et al.. (2024). Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects. Experimental Hematology and Oncology. 13(1). 31–31. 6 indexed citations
4.
Lin, Zhengjun, Guoqing Li, Ke Jiang, Zhihong Li, & Tang Liu. (2024). Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications. Molecular Cancer. 23(1). 191–191. 25 indexed citations
5.
Zhang, Zhiming, et al.. (2024). SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation. The FASEB Journal. 38(14). e23783–e23783. 5 indexed citations
6.
Lin, Zhengjun, et al.. (2024). The crosstalk of CD8+ T cells and ferroptosis in cancer. Frontiers in Immunology. 14. 1255443–1255443. 42 indexed citations
7.
Zeng, Min, et al.. (2024). Risk/benefit trade-off of habitual physical activity and air pollution on mortality: A large-scale prospective analysis in the UK Biobank. Ecotoxicology and Environmental Safety. 279. 116471–116471. 2 indexed citations
8.
Lin, Zhengjun, Mingrui Wang, Lifan Wang, et al.. (2024). Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. European journal of medical research. 29(1). 12–12. 3 indexed citations
9.
Liang, Luxin, Zhengjun Lin, Ziqing Duan, et al.. (2024). Enhancing the immunomodulatory osteogenic properties of Ti-Mg alloy by Mg2+-containing nanostructures. Regenerative Biomaterials. 11. 4 indexed citations
10.
Lin, Zhengjun, Changchun Li, Xiao Lin, et al.. (2024). Adipose exosomal noncoding RNAs: Roles and mechanisms in metabolic diseases. Obesity Reviews. 25(6). e13740–e13740. 4 indexed citations
11.
Lin, Zhengjun, et al.. (2024). Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways. Phytotherapy Research. 38(6). 2860–2874. 8 indexed citations
12.
Zheng, Tao, et al.. (2023). Pogostone attenuates osteolysis in breast cancer by inhibiting the NF-kB and JNK signaling pathways of osteoclast. Life Sciences. 328. 121611–121611. 5 indexed citations
13.
Zhou, Jian, Yihan Li, Rongjun Wan, et al.. (2023). Association of oily fish and nonoily fish intakes with all-cause mortality and cause-specific mortality: a large population-based prospective study. Journal of Translational Medicine. 21(1). 280–280. 4 indexed citations
14.
Wu, Yanlin, Zhengjun Lin, Changchun Li, et al.. (2023). Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduction and Targeted Therapy. 8(1). 98–98. 222 indexed citations breakdown →
15.
Lin, Zhengjun, Jian Zhou, Guoqing Li, et al.. (2023). Exosomal circRNAs in cancer: Implications for therapy resistance and biomarkers. Cancer Letters. 566. 216245–216245. 43 indexed citations
16.
Zhou, Jian, et al.. (2022). Transcriptome Sequencing Analysis of lncRNA and mRNA Expression Profiles in Bone Nonunion. Oxidative Medicine and Cellular Longevity. 2022(1). 9110449–9110449. 2 indexed citations
17.
Zhou, Jian, et al.. (2022). Association between glucosamine use and cancer mortality: A large prospective cohort study. Frontiers in Nutrition. 9. 947818–947818. 10 indexed citations
18.
Lin, Zhengjun, et al.. (2021). Prognostic and clinicopathological value of circPVT1 in human cancers: A meta‐analysis. Cancer Reports. 4(5). e1385–e1385. 6 indexed citations
19.
Lin, Zhengjun, et al.. (2020). Noncoding RNAs in drug-resistant pancreatic cancer: A review. Biomedicine & Pharmacotherapy. 131. 110768–110768. 30 indexed citations
20.
Lin, Zhengjun, et al.. (2020). Cellular plasticity and drug resistance in sarcoma. Life Sciences. 263. 118589–118589. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhongqiu Zhou Breakdown of academic impact, for papers by Meng Ye Breakdown of academic impact, for papers by Qingdong Guo Breakdown of academic impact, for papers by Xiaoming Hou Breakdown of academic impact, for papers by Dongmei Zhou Breakdown of academic impact, for papers by Pinglin Lai Breakdown of academic impact, for papers by Meng Xue
Rankless by CCL
2026